TILT 234
Alternative Names: Ad3-hTERT-CMV-hCD40LLatest Information Update: 30 Nov 2023
At a glance
- Originator TILT Biotherapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours